Molecular subtyping matters

Not all breast cancers respond the same to neoadjuvant therapy.
BluePrint identified and reclassified 13% of clinically Luminal type patients (ER+ by IHC) as genomically Basal-type. In response to neoadjuvant chemotherapy, these ER+, Basal-type tumors had a Pathological Complete Response (pCR) rate of 34.5%, similar to pCR rate (37.6%) of triple negative; much greater pCR than Luminal-B (5.6%) or Luminal-A (2.3%) patients.

Evidence matters for node positive patients

Not all lymph node positive breast cancers are the same. Only mammaprint is recommended by all major guidelines for node positive patients.

In MINDACT, clinical prospective randomised MammaPrint trial of 6,693 early stage patients including 700 LN+ patients; 48% of clinically high risk patients were genomically "Low Risk" by MammaPrint + BluePrint and spared chemotherapy.
Furthermore 96% of 1-3 LN+ MammaPrint low risk patients were treated with only adjuvant endocrine therapy.
MammaPrint + BluePrint results in combination enables the Oncologist to make the best treatment decision for the breast cancer patient.

MammaPrint + BluePrint tests are run at the same time on the same tumor tissue sample (FFPE) to provide results in ten days. This is the only FDA cleared test that is designed for women of all ages who:
• Are newly diagnosed with invasive early-stage breast cancer (Stage I or II)
• Have a tumor size up to 5 cm
• Are either lymph node-negative or have 1-3 positive lymph nodes

Your care should be as unique and individualised as you are!

I am an educationist, a wife, a mother and a breast cancer survivor. I thought everyone who gets breast cancer diagnosis gets the same treatment but I learned that is not the case. After surgery at Shifa International Hospital, I met with my radiation oncologist and he recommended a genomic test MammaPrint+BluePrint to help determine the expected course of my disease and treatment options. It is a binary test with definitive answers, either you are “Low Risk” or “High Risk” for recurrence. I decided to get my tumor tissue block tested and received the results in two weeks.

I believe every patient should understand their treatment and how it impacts their quality of life. I am so thankful I had the MammaPrint+BluePrint test and it came back that I was "Low Risk" and did not need chemotherapy.

Allah is merciful. The test results changed my life physically and emotionally. My treatment plan after surgery was adjuvant endocrine therapy.

I feel cured.

Mrs Durrani - 2019

Over 75,000 women worldwide have chosen MammaPrint to help evaluate their risk of breast cancer recurrence. BluePrint test helps predict tumor behavior and better predict a patient's prognosis.

Every woman deserves a unique treatment strategy.

Resources